Blueprint Medicines Long Term Debt

Blueprint Medicines (BPMC) currently reports a long-term debt of $65M as of March 2025. That compares with $430M in the prior-year period — down 84.9% year over year. Use the charts on this page to explore Blueprint Medicines's long-term debt history and peer comparisons.

Blueprint Medicines's long-term debt decreased from $430M to $65M — a 84.9% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Blueprint Medicines reported $65M in long-term debt as of March 2025. That compares with $430M in the prior-year period — down 84.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $65M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.

Blueprint Medicines is classified in the Healthcare sector. On long-term debt, it currently shows $65M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BPMC with unrelated industries.